NEW YORK (GenomeWeb) – Agendia said on Thursday that its MammaPrint 70-gene signature breast cancer recurrence risk test is now covered by Blue Shield of California.

According to the company, the payor has updated its medical policy to state that "the use of MammaPrint is considered medically necessary in women who are diagnosed with primary invasive breast cancer."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.